Filipe, da S., , Hughes, J. ., Aranday-Cortes, E. ., Irving, W. ., Foster, G. ., … Thomson, E. . (2018). Reply to: No effect of resistance-associated substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing regimens. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2017.11.044 (Original work published 2018)

Levin, M. ., Ustianowski, A. ., De Wit, S. ., Launay, O. ., Avila, M. ., Templeton, A. ., … Study, G. P. (2022). Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. The New England Journal of Medicine, 386(23), 2188-2200. https://doi.org/10.1056/NEJMoa2116620 (Original work published 2022)